Table 1. The characteristic of randomized clinical trials.
| Study | Aouthors | Year | Regimens | ITT | Dose of X | Dose of T | Follow-up |
|---|---|---|---|---|---|---|---|
| FinXX | Joensuu H | 2012 | TX-CEX | 751 | 900 mg/m2 bid | 60 mg/m2 | 5 |
| T-CEF | 745 | 80 mg/m2 | |||||
| US Oncology Group | O’Shaughnessy J | 2015 | AC-TX | 1307 | 825 mg/m2 bid | 75 mg/m2 | 5 |
| AC-T | 1304 | 100 mg/m2 | |||||
| Shao Z | Shao Z | 2016 | TX-CEX | 288 | 1000 mg/m2 bid | N/A | 2.5 |
| T-CEF | 273 | N/A | |||||
| Ohno S | Ohno S | 2013 | CEF-TX | 239 | 825 mg/m2 bid | 75 mg/m2 | 4.5 |
| CEF-T | 238 | 75 mg/m2 | |||||
| GeparQuattro | von Minckwitz G | 2014 | EC-TX | 471 | 900 mg/m2 bid | 75 mg/m2 | 5.4 |
| EC-T | 471 | 100 mg/m2 | |||||
| NSABP B-40 | Bear HD | 2015 | TX-AC | 400 | 825 mg/m2 bid | 75 mg/m2 | 4.7 |
| T-AC | 394 | 100 mg/m2 | |||||
| ABCSG-24 | Steger GG | 2013 | EDX | 270 | 1000 mg/m2 bid | 75 mg/m2 | N/A |
| ED | 266 | 75 mg/m2 |
ITT = intent-to-treat; X = capecitabine; T = docetaxel; C = cyclophosphamide; E = epeirubicin; A = doxorubicin; F = fluorouracil; D = docetaxel. N/A = Not available.